Advertisement
(Photo: http://www.newscom.com/cgi-bin/prnh/20071227/CNTH002 )
I. Quality Facilities: New cGMP Pilot Plant and R&D Building becameOperational in October, 2007
Advertisement
The new Asymchem Life Science (Tianjin) Co., Ltd site began operation withthe opening of its new cGMP Pilot Plant in October 2007 and projected openingof a new R&D Building 1Q 2008. The initial investment for the site to date is180 million RMB, with further construction on-going for completion in late2008.
A total investment of 480 million RMB has been allotted for the 100,000sqm site located in TEDA, Tianjin, one of the more prestigious high tech parksin China. Asymchem will build cGMP production facilities following ICH Q7Aguidelines. Supporting facilities at this site will include an R&D center, ananalytical research center and an EHS center that follow internationalstandards. The goal is to achieve comprehensive facilities for development andproduction of cGMP intermediates and APIs at kilogram to mton scale. In theend, Asymchem will be in position to provide a variety of advanced technicalservices for pharmaceutical and biotech companies.
Phase I construction of Asymchem Life Science aims to build 12 separatecGMP production modules in a 50,000 sqm facility. Following ICH Q7Aguidelines, these production modules with a total output of approximately 20mtof cGMP intermediate and APIs each year are designed according tointernational concepts and are equipped with advanced HVAQ systems. So far,many intermediates and API's of high value have been manufactured in this newfacility.
In the meantime, a new R&D building with a construction area of 10,000 sqmwill be built to allow >300 chemists working at the same time. This new R&Dcenter, supported with sophisticated analytical instruments will be anecessary expansion of current R&D and Analytical Research capabilities. It isexpected that the whole construction of Asymchem Life Science will complete in2008. As a result, Asymchem's total production value will be of dynamic valueto the pharmaceutical industry.
''Asymchem will be even better positioned to serve foreignpharmaceutical/biotech customers in a more professional and international wayin the future. We will further increase our capacity in the production ofpharmaceutical intermediates and drug substances and will build ourselves to aone-stop shop to international pharmas by means of combination of CMO andCRO,'' stated Dr. Hao Hong, Chairman & CEO of Asymchem. The operation of newcGMP production facility and R&D center will turn an important page forAsymchem's investment in China. Advanced development concept and unparalleledtechnologies will definitely drive the domestic industry to better serveinternational pharmaceutical and biotech companies.
II. Personnel Training: Asymchem's China Personnel Training Base Completesas Asymchem's Campus Recruitment grows nationally
On July 29, 2007, Asymchem's China Personnel Training Base is complete inDunhua, Jilin province. With a modern design equipped with advanced multi-media systems, the base allows >60 people to meet together at the same time.Asymchem envisions this as a place for brainstorming, for delivery of companyconcepts and for employee enrichment. In July of 2007, the 3rd annual Asymchemmanagement meeting was held in the base.
Dr. Hao Hong emphasized, ''Talent development always is the most vitalpart of Asymchem development and we always value this part highly.'' Thecompletion of Asymchem's China Personnel Training Base enhances personneltraining, delivers management concepts and, at the same time, en
